Entropy Neurodynamics Limited (ENP) - Net Assets
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has net assets worth AU$7.36 Million AUD (≈ $5.21 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$8.38 Million ≈ $5.93 Million USD) and total liabilities (AU$1.02 Million ≈ $722.06K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ENP strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$7.36 Million |
| % of Total Assets | 87.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -16.39% |
| 10-Year Change | N/A |
| Growth Volatility | 104.19 |
Entropy Neurodynamics Limited - Net Assets Trend (2018–2026)
This chart illustrates how Entropy Neurodynamics Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Entropy Neurodynamics Limited stock valuation.
Annual Net Assets for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual net assets of Entropy Neurodynamics Limited from 2018 to 2026. Also explore net asset momentum of Entropy Neurodynamics Limited to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | AU$7.36 Million ≈ $5.21 Million |
+23.47% |
| 2025-06-30 | AU$5.96 Million ≈ $4.22 Million |
+6.12% |
| 2024-06-30 | AU$5.62 Million ≈ $3.98 Million |
+36.18% |
| 2023-06-30 | AU$4.13 Million ≈ $2.92 Million |
-53.14% |
| 2022-06-30 | AU$8.81 Million ≈ $6.23 Million |
-53.32% |
| 2021-06-30 | AU$18.87 Million ≈ $13.35 Million |
+276.03% |
| 2020-06-30 | AU$5.02 Million ≈ $3.55 Million |
-2.00% |
| 2019-06-30 | AU$5.12 Million ≈ $3.62 Million |
+70540.08% |
| 2018-06-30 | AU$-7.27K ≈ $-5.14K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Entropy Neurodynamics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4009799700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$41.11 Million | 558.30% |
| Other Comprehensive Income | AU$6.53 Million | 88.63% |
| Total Equity | AU$7.36 Million | 100.00% |
Entropy Neurodynamics Limited Competitors by Market Cap
The table below lists competitors of Entropy Neurodynamics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Digihost Technology Inc
V:DGHI
|
$48.56 Million |
|
Indonesia Energy
NYSE MKT:INDO
|
$48.56 Million |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
$48.61 Million |
|
Cherrybro co.Ltd
KQ:066360
|
$48.61 Million |
|
Viewbix Inc. Common Stock
NASDAQ:VBIX
|
$48.54 Million |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
$48.54 Million |
|
Elton International Trading Company S.A
AT:ELTON
|
$48.52 Million |
|
Analabs Resources Bhd
KLSE:7083
|
$48.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Entropy Neurodynamics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 5,963,916 to 7,363,742, a change of 1,399,826 (23.5%).
- Net loss of 4,869,067 reduced equity.
- Other comprehensive income increased equity by 470,843.
- Other factors increased equity by 5,798,050.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.87 Million | -66.12% |
| Other Comprehensive Income | AU$470.84K | +6.39% |
| Other Changes | AU$5.80 Million | +78.74% |
| Total Change | AU$- | 23.47% |
Book Value vs Market Value Analysis
This analysis compares Entropy Neurodynamics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | AU$0.00 | AU$0.04 | x |
| 2019-06-30 | AU$0.20 | AU$0.04 | x |
| 2020-06-30 | AU$0.12 | AU$0.04 | x |
| 2021-06-30 | AU$0.32 | AU$0.04 | x |
| 2022-06-30 | AU$0.12 | AU$0.04 | x |
| 2023-06-30 | AU$0.05 | AU$0.04 | x |
| 2024-06-30 | AU$0.01 | AU$0.04 | x |
| 2025-06-30 | AU$0.00 | AU$0.04 | x |
| 2026-06-30 | AU$0.00 | AU$0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Entropy Neurodynamics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -66.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-66.12%) is above the historical average (-82.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | AU$-173.87K |
| 2019 | -44.59% | 0.00% | 0.00x | 1.05x | AU$-2.79 Million |
| 2020 | -105.21% | 0.00% | 0.00x | 1.30x | AU$-5.78 Million |
| 2021 | -44.88% | 0.00% | 0.00x | 1.14x | AU$-10.35 Million |
| 2022 | -114.49% | -10111.31% | 0.01x | 1.55x | AU$-10.96 Million |
| 2023 | -172.77% | -1152.70% | 0.11x | 1.43x | AU$-7.54 Million |
| 2024 | -109.30% | -548.74% | 0.15x | 1.33x | AU$-6.70 Million |
| 2025 | -89.41% | -335.91% | 0.24x | 1.12x | AU$-5.93 Million |
| 2026 | -66.12% | 0.00% | 0.00x | 1.14x | AU$-5.61 Million |
Industry Comparison
This section compares Entropy Neurodynamics Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $7,433,724
- Average return on equity (ROE) among peers: -298.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Entropy Neurodynamics Limited (ENP) | AU$7.36 Million | 0.00% | 0.14x | $48.55 Million |
| Adalta Ltd (1AD) | $5.38 Million | -112.69% | 0.98x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $3.14 Million | 0.00% | 0.26x | $12.88 Million |
| ACRUX Ltd (ACR) | $9.09 Million | -108.18% | 0.68x | $2.91 Million |
| Actinogen Medical Ltd (ACW) | $12.13 Million | -29.97% | 0.07x | $130.32 Million |
| Argenica Therapeutics Ltd (AGN) | $18.40K | -2084.05% | 19.53x | $13.63 Million |
| Arovella Therapeutics Ltd (ALA) | $19.30 Million | -17.45% | 0.18x | $50.46 Million |
| Anatara Lifesciences Ltd (ANR) | $535.97K | -364.70% | 1.14x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $6.93 Million | -92.79% | 0.30x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $11.42 Million | -39.44% | 0.30x | $45.40 Million |
| Avecho Biotechnology Ltd (AVE) | $6.40 Million | -134.59% | 0.29x | $54.68 Million |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more